16 February 2012

TiGenix announces changes in management responsibilities.

Leuven (BELGIUM) – February 16, 2012 – TiGenix (NYSE Euronext: TIG) announced today changes to executive responsibilities within the Company. Gil Beyen, co-founder and Chief Business Officer of TiGenix will hand over part of his responsibilities to take on a mandate outside TiGenix. Gil remains a member of the Board of Directors and the Company’s Chief Business Officer. Leading his senior business development team, he will focus on corporate and business development for TiGenix, and transfer his investor relations activities to Claudia D’Augusta, Chief Financial Officer.

“We are grateful that we can continue to benefit from Gil’s experience and expertise, while respecting his wish to expand his horizon after his eleven year tenure at the helm of TiGenix,” said Willy Duron, Chairman of the Board of Directors.

About TiGenix

TiGenix NV (NYSE Euronext Brussels: TIG) is a leading European cell therapy company with two marketed products for cartilage repair, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of
Leuven (Belgium) and has operations in Madrid (Spain), Cambridge (UK) and Sittard-Geleen (the Netherlands). For more information please visit www.tigenix.com.

For more information:


Eduardo Bravo
Chief Executive Officer


Gil Beyen
Chief Business Officer


Hans Herklots
Director Investor & Media Relations
+32 16 39 79 73